Pfizer has received approval from the FDA for Eraxis to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40%. In clinical studies, Eraxis was as well tolerated and the total number of drug-related adverse events was comparable to fluconazole. Eraxis has not been associated with renal toxicity and has no clinically relevant drug-to-drug interacti...